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Abstract: For more than a decade, we have developed stable isotope dilution mass spectrometry methods to quantify key 
intermediates in cholesterol and bile acid biosynthesis, mevalonate and oxysterols, respectively. The methods are more 
sensitive and reproducible than conventional radioisotope (RI), gas-chromatography (GC) or high-performance liquid 
chromatography (HPLC) methods, so that they are applicable not only to samples from experimental animals but also to 
small amounts of human specimens. In this paper, we review the development of stable isotope dilution mass spectrometry 
for quantifying mevalonate and oxysterols in biological materials, and demonstrate the usefulness of this technique.
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Pathways for Cholesterol and Bile Acid Biosynthesis
Cholesterol homeostasis in human is maintained by two input pathways, comprised of dietary absorp-
tion and de novo synthesis, and two output pathways, comprised of direct secretion from liver to bile 
and conversion into bile acids (Everson, 1992). The rate-limiting step in the de novo cholesterol syn-
thesis is the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) into mevalonic acid (MVA) 
by HMG-CoA reductase (HMGCR) (Dietschy and Brown, 1974). In contrast, the bile acid biosynthetic 
pathway is initiated by either hepatic 7α-hydroxylation or hepatic and extrahepatic 27-hydroxylation 
of cholesterol. The former is catalyzed by microsomal cholesterol 7α-hydroxylase (CYP7A1), the ﬁ  rst 
and rate-limiting enzyme in the classic pathway, while the latter is catalyzed by mitochondrial sterol 
27-hydroxylase (CYP27A1), a key enzyme in the alternative pathway (Vlahcevic et al. 1992). Bile acid 
synthesis by the classic pathway accounts for more than 90% of total bile acids in humans (Duane and 
Javitt, 1999) while less than 50% of total bile acids is produced by this pathway in rats (Vlahcevic et al. 
1997) and mice (Schwarz et al. 1996). Therefore, the measurement of CYP7A1 activity is more impor-
tant than that of CYP27A1 activity for the evaluation of bile acid biosynthesis in humans.
Direct and Indirect Assays of HMGCR and CYP7A1 Activities
Since HMGCR and CYP7A1 are crucial enzymes in understanding whole body cholesterol metabolism, 
a great deal of effort has been made to develop suitable assay methods for these enzyme activities. The 
primary methods have the great disadvantage that an invasive tissue biopsy is necessary for direct 
determination of these enzyme activities in humans. To overcome this problem, plasma biomarkers for 
evaluation of these enzyme activities has been explored.
Plasma levels of MVA, the immediate product of HMGCR, were positively correlated with HMGCR 
activities in rat liver (Popjak et al. 1979). In humans, the plasma MVA concentrations reﬂ  ected (i) 
increased rates of whole-body cholesterol synthesis by treatment with cholestyramine resin, and (ii) 
decreased rates of whole-body sterol synthesis after consumption of a cholesterol-rich diet (Parker et al. 
1982 and 1984). In addition, plasma concentration of lathosterol, an intermediate in the late cholesterol 
biosynthetic pathway, was reported to reﬂ  ect hepatic HMGCR activity (Björkhem et al. 1987a) as well 
as whole body cholesterol synthesis (Kempen et al. 1988) in humans.46
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As for bile acid biosynthesis, Björkhem et al. 
(Björkhem et al. 1987b) demonstrated that serum 
levels of 7α-hydroxycholesterol (7A) correlated 
well with the activities of CYP7A1 in patients with 
gallstones treated with cholestyramine. In addition, 
Axelson et al. (Axelson et al. 1988) measured 
serum concentrations of 7α-hydroxy-4-cholesten-
3-one (C4), the product of the next reaction fol-
lowing 7α-hydroxylation of cholesterol, and 
showed that it was a good marker for CYP7A1 
activity in humans (Axelson et al. 1991). It was 
subsequently reported that serum concentrations 
of 7A (Hahn et al. 1995) and C4 (Sauter et al. 1996) 
reﬂ  ected not only CYP7A1 activities but also bile 
acid synthesis in humans.
The Methods for the Quantiﬁ  cation 
of MVA
Table 1 summarizes the previously described 
methods for the quantiﬁ  cation of MVA in the 
liver (enzyme assay), plasma or urine. The pri-
mary methods for assaying HMGCR activity 
have utilized a RI technique that measures the 
radioactivity in [
14C]MVA produced from 
[
14C]HMG-CoA (Shapiro et al. 1969; Goldfarb 
and Pitot, 1971; Shefer et al. 1972). The methods 
have been used for the direct determination of 
enzyme activity but they are not applicable to 
the quantiﬁ  cation of plasma or urinary MVA. 
In contrast, the following methods, i.e. 
radioenzymatic assay, enzyme immunoassay, gas 
chromatography-mass spectrometry (GC-MS), 
high-performance liquid chromatography 
(HPLC), liquid chromatography-mass spectrom-
etry (LC-MS) and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS), can measure 
not only enzyme activity but also MVA concen-
trations in plasma and urine.
Radioenzymatic assay
Radioenzymatic assay of the plasma MVA 
concentration was reported by Popjak et al. (Popjak 
et al. 1979). The method depends on the phos-
phorylation of MVA with [γ-
32P]ATP and MVA 
kinase to 5-[
32P]phospho-MVA, and the subsequent 
isolation of the 5-[
32P]phospho-MVA together with 
known amounts of added 5-phospho[
14C]MVA by 
ion-exchange chromatography. The detection limit 
of their radioenzymatic assay was 1–2 pmol 
(148–296 pg) indicating that it was not adequate 
for determining MVA in small amounts of plasma. 
In addition, there was a safety concern due to the 
handling of radioactive materials.
Enzyme immunoassay
In 1998, Hiramatsu et al. developed an enzyme 
immunoassay for urinary MVA using a speciﬁ  c 
monoclonal antibody against MVA (Hiramatsu 
et al. 1998). This method is not only simpler than 
the previously described radioenzymatic assay but 
also completely avoids the risk of radiation haz-
ards. However, the limit of detection was not bet-
ter than that of the radioenzymatic assay.
GC-MS
In 1972, Hagenfeldt and Hellström attempted to 
determine MVA concentration in rat blood by using 
GC-MS (Hagenfeldt and Hellström, 1972). In this 
procedure, the MVA was extracted from the acid 
aqueous phase as the lactone. The lactonization 
increased the hydrophobicity of MVA, so that they 
could extract it into organic phase. The resulting 
extract was treated with diazomethane to convert 
the coexisting fatty acids into their methyl esters. 
The unchanged mevalonolactone (MVL) with 
diazomethane in the extract was quantiﬁ  ed by GC-
MS in electron ionization mode (GC-EI-MS). The 
peak corresponding to the retention time of MVL 
appeared large due to interfering materials, such 
as fatty acids. However, the MVL could be quanti-
ﬁ  ed selectively because MVL exhibited an inten-
sive peak at m/z 71 in the spectrum, whereas all 
fatty acid methyl esters gave rise to the inherent 
peak at m/z 74 produced by the McLafferty rear-
rangement ion of the methyl ester. Since then, 
urinary MVA has been successfully quantiﬁ  ed by 
a similar GC-EI-MS method described above 
(Woollen et al. 2001).
In the 1970s, the RI technique was the standard 
method for assaying HMGCR activity, but the 
handling of radiolabeled materials was a great 
disadvantage of this method. In 1978, Miyazaki 
et al. developed a new non-RI method for assaying 
HMGCR activity in rat liver microsomes or liver 
slices using [
2H3]HMG-CoA as a substrate and 
GC-MS in chemical ionization mode (GC-CI-MS) 
(Miyazaki et al. 1978). In this method, the resulting 
[
2H3]MVL was derivatized to the corresponding 
n-propylamide-n-butylboronate, and deuterium 
labeled [
2H7]MVL was ﬁ  rst used as an internal 
standard.47
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Table 1. Methods for quantiﬁ  cation of MVA in biological samples.
Author Year Method 
(ionization 
mode)
Derivatization Lower 
limit of 
detection
Intra-assay 
variation
Inter-assay 
variation
Recovery Application
Hagenfeldt 
et al.
1972 GC-MS 
(P-EI)
MVL NA NA 6.2% 87% ± 4% blood
Miyazaki 
et al.
1978 GC-MS 
(P-CI)
MVL- PABB NA NA NA NA liver
Popjak 
et al.
1979 radioenzy-
matic 
assay
5-[
32P]phospho-
MVA
150–300 
pg
NA NA 100% plasma
Cighetti 
et al.
1981 GC-MS 
(P-EI)
MVL-TMS NA 1.5% 6.1% NA liver
Del Puppo 
et al.
1989 GC-HR-MS 
(P-EI)
MVL-TMS NA 6.5% NA 101% ± 4% plasma 
urine
Honda 
et al.
1991 GC-HR-MS 
(P-EI)
MVL-B-DMES 800 fg 4.9% 7.8% 96%–100% liver
Scoppola 
et al.
1991 GC-MS
(N-CI)
MVA-TFB-TMS 10 pg 5.1% 7.7% NA plasma
Yoshida 
et al.
1993 GC-HR-MS 
(P-EI)
MVL-B-DMES NA 2.8% 5.6% 91%–96% plasma
Ishihama 
et al.
1994 GC-MS 
(P-CI)
MVL NA 2.2% 4.5% 101%–103% plasma
Siavoshian 
et al.
1995 GC-MS 
(P-CI)
MVL-TMS NA 4.0% 8.0% 70% ± 2% urine
Saisho 
et al.
1997 GC-MS 
(N-CI)
MVA-PFB-CB NA 2.0% 7.5% 100%–107% plasma
Hiramatsu 
et al.
1998 enzyme 
immunoas-
say
MVA 195 pg 3.4% 5.2% 102% ± 7% urine
Woollen 
et al.
2001 GC-MS 
(P-EI)
MVL NA 13.7% 9.8% 82%–110% urine
Park et al. 2001 LC-MS 
(P-ESI)
MVL 6.5 pg 4.1% 9.4% 95% ± 4% liver
Ndong-
Akoume 
et al.
2002 LC-MS/MS 
(P-ESI)
MVL NA 1.0% NA 98%–99% liver
Abrar et al. 2002 LC-MS/MS 
(P-ESI)
MVL NA 4.1%–15% 13%–16% 89%–114% plasma
Jemal et al. 2003 LC-MS/MS 
(N-ESI)
MVA NA 4.5% 3.3% 98%–103% plasma 
urine
Buffalini 
et al.
2005 HPLC-UV MVL 741 ng NA 3.0% 97%–103% liver
Saini et al. 2006 LC-MS/MS 
(N-ESI)
MVA NA 1%–17% 3%–12% 99%–108% plasma
Honda 
et al.
2007 LC-MS/MS 
(P-ESI)
MV-PLEA 31 fg 1.8% 3.2% 93%–96% liver
Abbreviations: P-EI: positive electron ionization; NA: not available; P-CI: positive chemical ionization; N-CI: negative chemical ionization; 
MVL-PABB: MVL n-propylamide-n-butylboronate; MVL-TMS: trimethylsilyl ether of MVL; GC-HR-MS: high-resolution GC-MS; MVL-B-DMES: 
dimethylethylsilyl ether of mevalonylbenzylamide; MVA-TFB-TMS: trimethylsilyl ether of bis(triﬂ  uoromethyl)benzyl ester of MVA; MVA-PFB-
CB: cyclic boronate-pentaﬂ  uorobenzyl ester of MVA; P-ESI: positive electrospray ionization; N-ESI: negative electrospray ionization; HPLC-
UV: high-performance liquid chromatography equipped with an ultraviolet detector; MV-PLEA: MV-(2-pyrrolidin-1-yl-ethyl)-amide.48
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In 1991, Scoppola et al. (Scoppola et al. 1991) 
extended this approach, and quantiﬁ  ed plasma 
MVA concentrations. The MVA was lactonized, 
extracted with [
2H3]MVL and reconverted to the 
free acid. The resulting MVA was then converted 
to 3,5-bis(triﬂ  uoromethyl)benzyl ester followed 
by its trimethylsilyl (TMS) ether derivative. The 
quantiﬁ  cation method was based on GC-CI-MS 
using ammonia as a reagent gas and the detection 
limit of MVA in plasma was 100 pg/mL. The GC-
CI-MS method for the quantiﬁ  cation of plasma 
MVA was subsequently improved by Ishihama 
et al. (Ishihama et al. 1994) and Saisho et al. 
(Saisho et al. 1997), and the method for the deter-
mination of urinary MVA was developed by 
Siavoshian et al. (Siavoshian et al. 1995). How-
ever, the GC-CI-MS methods have one disadvan-
tage in that they required frequent cleaning of the 
CI ion source to maintain the high sensitivity.
To eliminate the aforementioned tedious opera-
tions in GC-CI-MS, another approach by gas 
chromatography-electron ionization-mass spec-
trometry (GC-EI-MS) was also developed. Cighetti 
et al. (Cighetti et al. 1981; Galli Kienle, 1984) 
assayed HMGCR activity by GC-EI-MS after 
conversion of MVL into the corresponding trimeth-
ylsilyl (TMS) ether. They used the ions at m/z 187 
(M–15) for MVL-TMS and m/z 150 (M–15–
CH2CO) for [
2H5]MVL-TMS because these ions 
were not inﬂ  uenced by interfering peaks in extracts 
from liver microsomes. In 1989, the same group 
improved their original method by using GC-high-
resolution (HR)-EI-MS (Del Puppo et al. 1989). 
This group lactonized plasma and urinary MVA 
into MVL using a cation exchange resin, and 
extracted with organic solvent after the addition of 
[
2H5]MVL as an internal standard. The extracted 
MVL was then converted into the TMS ether 
derivative, and quantiﬁ  ed by GC-HR-EI-MS with 
a mass spectral resolution of 5,000. The ions at 
m/z 145.0685 for MVL-TMS and m/z 150.0965 
for [
2H5]MVL-TMS were used for selected ion 
monitoring (SIM).
We also developed new assay methods to mea-
sure hepatic HMGCR activity (Honda et al. 1991) 
and plasma MVA concentration (Yoshida et al. 
1993) by GC-HR-EI-MS. These methods made it 
possible to simultaneously quantify not only MVA 
but also 7A. Other features of these methods are 
described below.
(i) A puriﬁ  cation procedure was developed by 
the serial use of commercially available solid-phase 
extraction cartridges, which provided high recovery 
and reproducibility. In brief, plasma MVA was 
extracted by an anion exchange Bond Elut SAX 
cartridge, and then eluted as MVL with 0.6 M HCl. 
The MVL was further puriﬁ  ed by a reversed phase 
Bond Elut C18 and a normal phase Bond Elut CN 
cartridges. In addition, an excess benzylamine was 
removed by another Bond Elut CN cartridge after 
derivatization into mevalonylbenzylamide. The 
recovery of spiked MVA through the puriﬁ  cation 
procedures using these cartridges was 94.1%, and 
the relative standard deviations between sample 
preparations and between measurements by this 
method were 5.6% and 2.8%, respectively (Yoshida 
et al. 1993).
(ii) [
2H7]MVL was used as an internal stan-
dard. This hepta-deuterated variant of MVL 
provided both good linearity of the calibration 
curve and easiness to distinguish between MVL 
peak and interfering peaks even if the MVL peak 
was small.
(iii) MVL was easily converted into mevalon-
ylbenzylamide without any catalyst under mild 
conditions followed by its dimethylethylsilyl 
(DMES) ether derivative. This amidation via MVL 
from MVA is a characteristic reaction for γ-
hydroxyfatty acids, such as MVA, however, the 
free fatty acids also present in the extract did not 
react without catalysts. The resulting derivative 
gave a [M-C2H5]
+ ion at m/z 380.2077 with a 
prominent intensity in the high mass region, which 
was a great advantage in the elimination of interfer-
ing peaks originating from endogenous substances 
in the extract by GC-EI-MS.
(iv) The DMES ether derivative was much more 
stable than the TMS ether derivative.
(v) The MVL derivative was quantiﬁ  ed by GC-
HR-EI-MS with a mass spectral resolution of 
10,000, which was also useful to eliminate peaks 
of unknown substances that could interfere with 
the monitoring.
(vi) Trace amounts, less than 1 pg, of MVA 
could be detected by this method, and the lower 
limit of quantification in plasma sample was 
180 pg/mL.
(vii) Using these methods, it was validated that 
there was a highly signiﬁ  cant correlation between 
the hepatic HMGCR activities and plasma concen-
trations of MVA in ten patients (r = 0.83, P  0.01) 
(Yoshida et al. 1993).
(viii) The GC-EI-MS method did not require 
frequent cleaning. This indicated that the GC-EI-MS 49
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method was suitable for clinical applications, in 
which it is necessary to assay a large number of 
samples at once.
LC-MS and LC-MS/MS
Since the early 2000s, LC-MS or LC-MS/MS have 
been used more extensively than GC-MS to ana-
lyze relatively polar compounds, such as MVA or 
MVL, because LC-MS and LC-MS/MS do not 
generally require a derivatization step.
Park et al. (Park et al. 2001) and Ndong-
Akoume et al. (Ndong-Akoume et al. 2002) 
assessed HMGCR activity by measuring MVL 
with LC-MS and LC-MS/MS using the positive 
electrospray ionization (P-ESI) mode. Plasma 
and urinary MVA concentrations were quantiﬁ  ed 
by LC-P-ESI-MS/MS after conversion into MVL 
(Abrar and Martin, 2002), as well as directly by 
LC-negative (N)-ESI-MS/MS without lactoniza-
tion (Jemal et al. 2003; Saini et al. 2006). The 
detection limit of MVL by the LC-MS method 
was 6.5 pg (Park et al. 2001), and the lower limit 
of quantiﬁ  cation of plasma MVA by the LC-
MS/MS methods were 200–500 pg/mL, which 
were similar to those obtained using GC-MS 
methods.
Recently, we developed a highly-sensitive 
method to assess HMGCR activity by LC-MS/MS 
(Honda et al. 2007a). In this method, MVA was 
extracted as MVL and its detection sensitivity was 
enhanced through derivatization (Fig. 1). The fea-
tures of this method are described below.
(i) The P-ESI mode was selected to quantify 
MVA because the positive mode provides more 
abundant ions than the negative mode (Hiraoka 
and Kudaka, 1992).
(ii) To select the most suitable derivative of 
MVA for P-ESI mode, the amidation reaction from 
MVA via MVL, a characteristic reaction for γ-
hydroxy fatty acids such as MVA, was conducted 
using seven types of primary alkylamines with a 
tertiary amine moiety to promote protonation. Of 
these amide derivatives, mevaonyl-2-pyrrolidin-
1-yl-ethyl)-amide (MV-PLEA) was the best 
derivative for the LC-P-ESI-MS/MS method.
(iii) The detection limit of this MV-PLEA was 
about 30 fg (signal-to-noise ratio (S/N) = 3), indi-
cating that this is the most sensitive method at 
present for the detection of MVL.
(iv) [
2H7]MVL was used as an internal standard. 
The recovery of spiked MVA was 94.6%, and the 
relative standard deviations between sample 
preparations and between measurements by this 
method were 3.2% and 1.8%, respectively.
(v) MV-PLEA was determined by selected reac-
tion monitoring (SRM) using m/z 245 (M+H) as a 
precursor ion and m/z 227 (M+H–H2O) as a prod-
uct ion, which almost completely eliminated the 
interfering peaks on the SRM chromatogram.
(vi) Hepatic HMGCR activities in 11 normal 
rats were measured by both the RI and LC-P-ESI-
MS/MS methods. The HMGCR activities obtained 
by the present method correlated well with those 
obtained by the conventional RI method (r = 0.93, 
P  0.0001). In the RI method, [
14C]HMG-CoA is 
usually used as 30 dpm/pmol = 33.3 fmol/dpm. 
When the standard deviation of background noise 
is 2 dpm, the signal would be 6 dpm when the 
S/N = 3. Therefore, the detection limit of the con-
ventional RI method is calculated to be 200 fmol 
(S/N = 3). In comparison, the detection limit of the 
LC-P-ESI-MS/MS method is 240 amol (S/N = 3), 
∼800 times more sensitive than that of the conven-
tional RI method.
HPLC
In 2005, Buffalini et al. reported a new method for 
the determination of HMGCR activity by HPLC 
(Buffalini et al. 2005). In this method, MVL pro-
duced from unlabeled HMG-CoA was extracted 
and quantiﬁ  ed by HPLC with a ﬁ  xed ultraviolet 
(UV) detector (200 nm). This method does not 
require very expensive equipment, such as a mass 
spectrometer, but the detection limit of MVL is at 
least 100,000 times less than that by mass spec-
trometry.
The methods for the quantiﬁ  cation 
of 7A
CYP7A1 activity has previously been assayed by 
measuring the radioactivity of 7A produced from 
exogenously added [
14C]cholesterol by incubation 
with liver microsomes (Shefer et al. 1968). How-
ever, the extent of equilibration of exogenous 
labeled cholesterol with the endogenous cholesterol 
pool under different conditions still remains to be 
elucidated. To overcome this problem, several meth-
ods, i.e. a radioisotope derivative method, and GC-
MS and HPLC methods, have been developed. 
These methods are able to measure the net amount 
of 7A produced from endogenous and exogenous 50
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cholesterol. Table 2 summarizes the previously 
reported methods for the direct determination of the 
mass of 7A in the liver (enzyme assay) or plasma.
Radioisotope derivative method
This technique can measure the net amount of 7A 
produced from exogenous [
14C]cholesterol and 
endogenous unlabeled cholesterol (Mitropoulos 
et al. 1972; Shefer et al. 1975). The resultant 7A 
was extracted, acetylated with [
3H]acetic anhydride 
and puriﬁ  ed by thin layer chromatography (TLC). 
The mass of 7A was calculated from the amount 
of radioactivity in the acetylated product based 
upon the speciﬁ  c radioactivity of the reagent.
Figure 1. Representative chromatogram of mevalonyl-(2-pyrrolidin-1-yl-ethyl)-amide (MV-PLEA) by positive ESI-SRM at m/z 245 → m/z 
227. Authentic standard of MV-PLEA (100 fg) was injected into the HPLC. LC-MS/MS conditions have been described previously (Honda 
et al. 2007a).
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GC-MS
In 1974, Björkhem and Danielsson developed a 
method for the assay of hepatic CYP7A1 activity 
by GC-MS (Björkhem and Danielsson, 1974). Their 
method was based on stable isotope dilution-mass 
spectrometry using [
2H3]7A as an internal standard. 
In this method, 7A produced from endogenous 
microsomal cholesterol was extracted in organic 
solvent, puriﬁ  ed by TLC, converted to the TMS 
ether derivative, and analyzed by GC-MS. In 1981, 
Sanghvi et al. reported an alternative method by 
GC-MS in which 7A produced from microsomal 
cholesterol was extracted with 5α-cholestane as an 
internal standard by organic solvent, converted to 
the TMS ether derivative, and quantiﬁ  ed by SIM 
(Sanghvi et al. 1981). Meanwhile, Yamashita et al. 
measured hepatic CYP7A1 activity by GC-SIM 
using 5α-cholestane-3β,7β-diol as an internal stan-
dard (Yamashita et al. 1989).
We also developed a new assay method for 
hepatic CYP7A1 activity by GC-HR-SIM 
(Honda et al. 1991). As mentioned in the previous 
MVA section, this method made it possible to 
quantify simultaneously not only 7A but also MVA. 
[
2H7]7A was used as an internal standard and 7A 
was converted into its DMES ether derivative 
before analysis by GC-HR-MS. This DMES ether 
derivative was not only more stable but also much 
advantageous compared with the TMS ether 
derivative for the separation of 7A from contami-
nated cholesterol on GC chromatograms.
The concentration of 7A in human serum was ﬁ  rst 
quantified by Björkhem et al. using GC-SIM 
(Björkhem et al. 1987b). They also showed that serum 
free (unesterified) 7A reflected hepatic CYP7A1 
activities in humans. In contrast, Oda et al. quantiﬁ  ed 
human serum free and esteriﬁ  ed 7A concentrations 
by GC-SIM and reported that the hepatic CYP7A1 
activities correlated better with the serum esteriﬁ  ed 
7A than with the free 7A (Oda et al. 1990).
In 1993, we applied our GC-HR-SIM method 
to the determination of human serum 7A concentrations 
Table 2. Methods for quantiﬁ  cation of 7A in biological samples.
Author Year Method 
(ionization 
mode)
Derivatization Lower
limit of 
detection
Intra-
assay 
variation
Inter-
assay 
variation
Recovery Application
Mitropoulos 
et al.
1972 radioisotope 
derivative 
method
acetylated 7A NA NA NA NA liver
Björkhem 
et al.
1974 GC-MS
(P-EI)
7A-TMS NA NA 2.2% 95% liver
Sanghvi 
et al.
1981 GC-MS
(P-EI)
7A-TMS 50 pg 3.5% 2.3%–4.7% NA liver
Noshiro 
et al.
1985 NP-HPLC-
UV
7A NA NA NA 85% liver
Ogishima 
et al.
1986 NP-HPLC-
UV
C4 NA NA NA NA liver
Björkhem 
et al.
1987 GC-MS
(P-EI)
7A-TMS 1–2 ng/mL NA 4%–8% 105% serum
Hylemon 
et al.
1989 RP-HPLC-
UV
C4 8 ng NA NA NA liver
Yamashita 
et al.
1989 GC-MS
(P-EI)
7A-TMS NA 3.8% 4.6% 92%–99% liver
Oda et al. 1990 GC-MS
(P-EI)
7A-TMS NA NA 3% 97%–109% serum
Honda 
et al.
1991 GC-HR-MS
(P-EI)
7A-DMES 1.6 pg 7.9% 7.0% 94%–102% liver
Yoshida 
et al.
1993 GC-HR-MS
(P-EI)
7A-DMES NA 4.2% 2.6% 93%–95% serum
Abbreviations: NA: not available; P-EI: positive electron ionization; 7A-TMS: trimethylsilyl ether of 7α-hydroxycholesterol; HPLC-UV: 
high-performance liquid chromatography equipped with an ultraviolet detector; NP: normal-phase; C4: 7α-hydroxy-4-cholesten-3-one; RP: 
reversed-phase; GC-HR-MS: high-resolution GC-MS; 7A-DMES: dimethylethylsilyl ether of 7α-hydroxycholesterol.52
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and conﬁ  rmed that there was a signiﬁ  cant correlation 
(r = 0.76,  p   0.05) between serum free 7A 
concentrations and hepatic CYP7A1 activities in 
humans (Yoshida et al. 1993). However, neither the 
esteriﬁ  ed 7A (r = 0.45, p  0.05) nor the total (free + 
esteriﬁ  ed) 7A concentrations (r = 0.51, p  0.05) cor-
related signiﬁ  cantly with CYP7A activities.
HPLC
The assay method for hepatic CYP7A1 activity by 
HPLC was ﬁ  rst reported by Noshiro et al. (Noshiro et al. 
1985). The 7A produced from microsomal cholesterol 
was extracted and separated by normal phase HPLC. 
Although the absorption maximum of 7A was lower 
than 200 nm, they monitored 7A at 214 nm because 
there was an interference due to absorption of oxygen 
and/or solvent impurities at lower wavelengths.
In 1986, the same group improved the assay 
method by converting the produced 7A into C4 by 
incubating with cholesterol oxidase (Ogishima 
et al. 1986). Because C4 exhibits an intense absorp-
tion at 240 nm and there are fewer interfering peaks 
at this wavelength than at 214 nm, this improved 
method exhibited a more than 10-fold increase in 
the sensitivity compared with the previous one 
(Noshiro et al. 1985). In 1989, Hylemon et al. 
modiﬁ  ed Ogishima’s method by using reverse-
phase HPLC and adding 7β-hydroxycholesterol as 
an internal standard (Hylemon et al. 1989).
The Methods for the Quantiﬁ  cation 
of C4
Another plasma or serum marker for the evaluation 
of hepatic CYP7A1 activities is C4, which is a 
product of the next oxidative enzymatic reaction 
after CYP7A1. In fact, CYP7A1 activities correlated 
better with serum C4 levels compared with those of 
7A irrespective of the esteriﬁ  cation (Yoshida et al. 
1994). Table 3 shows the previously described 
methods for the quantiﬁ  cation of serum C4 concen-
trations by HPLC, GC-MS, and LC-MS/MS.
HPLC
In 1988, Axelson et al. (Axelson et al. 1988) 
reported a method for the quantiﬁ  cation of plasma 
C4 using normal-phase HPLC with UV detection, 
and demonstrated that plasma C4 concentration 
reﬂ  ected bile acid biosynthesis in humans. In addi-
tion, they reported that there was a strong positive 
correlation between the plasma levels of C4 and 
the activities of CYP7A1 in patients treated with 
cholestyramine, chenodeoxycholic acid, or urso-
deoxycholic acid (Axelson et al. 1991). However, 
their method required the addition of 
3H-labeled 
25-hydroxyvitamin D3 as an internal standard. On 
the other hand, Pettersson et al. (Pettersson and 
Eriksson, 1994) and Gälman et al. (Gälman et al. 
2003) used unlabeled 7β-hydorxy-4-cholesten-3-
one as an internal standard and analyzed C4 levels 
using HPLC with a reversed-phase column. The 
detection limits of C4 by these HPLC-UV methods 
were nearly 1 ng, so that at least 1 mL of plasma 
was required for each assay.
GC-MS
In 1994, we developed a more sensitive method 
for the quantiﬁ  cation of plasma C4 by GC-HR-MS 
using [
2H7]C4 as an internal standard (Yoshida 
Table 3. Methods for quantiﬁ  cation of serum C4 concentration.
Author Year Method
(ionization 
mode)
Derivatization Lower
limit of
detection
Intra-
assay
variation
Inter-
assay
variation
Recovery Application
Axelson 
et al.
1988 NP-HPLC-
UV
C4 0.5–1.5 ng/mL NA 5% 82%–106% plasma
Pettersson 
et al.
1994 RP-HPLC-
UV
C4 3 ng 3.2% 3.8% 96%–105% serum
Yoshida 
et al.
1994 GC-HR-MS 
(P-EI)
C4-MO-DMES 1 pg 2.54% 5.16% 94%–100% plasma
Gälman 
et al.
2003 RP-HPLC-
UV
C4 500 pg 4.4% 5.6% NA blood
Honda
et al.
2007 LC-MS/MS 
(P-ESI)
C4-picolinate 30 fg 3.9% 5.7% 92%–94% serum
Abbreviations: HPLC-UV: high-performance liquid chromatography equipped with an ultraviolet detector; NA: not available; NP: normal-
phase; RP: reversed-phase; GC-HR-MS: high-resolution GC-MS; P-EI: positive electron ionization; C4-MO-DMES: methyloxime dimethyl-
ethylsilyl ether of C4; P-ESI: positive electrospray ionization.53
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et al. 1994). C4 was extracted from 200 μL of 
plasma by a salting-out extraction, and then puri-
ﬁ  ed by serial solid-phase extractions. The extract 
was treated with O-methylhydroxylamine hydro-
chloride and then dimethylethylsilylated. The 
resulting methyloxime-DMES ether derivative was 
quantiﬁ  ed by GC-HR-SIM. This method was very 
sensitive as well as speciﬁ  c, and a lower limit of 
detection of 1 pg was achieved.
We compared the relationships between hepatic 
CYP7A1 activity and plasma concentrations of C4 
and free 7A in humans using our GC-HR-SIM 
methods (Yoshida et al. 1994). Both biomarkers 
correlated signiﬁ  cantly with hepatic CYP7A1 activ-
ity (C4: r = 0.84, p  0.001; free 7A: r = 0.73, 
p  0.01), and C4 correlated better with CYP7A1 
activity compared with free 7A. However, perhaps 
these plasma markers do not precisely reflect 
hepatic CYP7A1 activities in some patients with 
markedly changed concentrations of plasma lipo-
proteins. Because plasma oxysterols including C4 
and 7A are transported in lipoproteins, the concen-
trations of oxysterols can be affected by the half-life 
of the lipoproteins. This hypothesis was supported 
by another study by ourselves (Honda et al. 2004), 
in which plasma C4 concentrations and hepatic 
CYP7A1 activities were compared in New Zealand 
white rabbits that were fed a high cholesterol diet 
and/or a bile ﬁ  stula was constructed. Feeding cho-
lesterol markedly increased and bile drainage 
reduced plasma cholesterol concentrations. Initially, 
in these models there was no correlation between 
plasma C4 concentrations and hepatic CYP7A1 
activities (r = −0.24, p  0.05). Cholesterol feeding 
was associated with downregulated CYP7A1 
activities, while plasma C4 concentrations were 
elevated in the presence of increased plasma cho-
lesterol levels. However, this discrepancy was 
overcome and a signiﬁ  cant correlation was observed 
(r = 0.73, p  0.05) by expressing C4 levels relative 
to cholesterol. These results suggested that plasma 
C4 relative to cholesterol was a better marker for 
hepatic CYP7A1 activity than the absolute concen-
tration when plasma cholesterol concentrations 
were changed markedly.
LC-MS/MS
HPLC with UV detection is a more convenient 
method than GC-MS for the measurement of 
plasma C4 concentrations. However, the sensitiv-
ity is not sufficient to quantify C4 in limited 
amounts of human serum. Therefore, we recently 
developed a highly-sensitive new method by LC-
MS/MS (Honda et al. 2007b). After the addition 
of [
2H7]C4 as an internal standard, C4 was 
extracted from human serum (2–50 μL) by a salt-
ing-out procedure, derivatized into the picolinoyl 
ester (C4-7α-picolinate), and then puriﬁ  ed using 
a disposable C18 cartridge. The resulting picolinoyl 
ester derivative of C4 was quantiﬁ  ed by LC-P-ESI-
MS/MS (Fig. 2). LC-MS/MS method do not 
always require a derivatization step. However, it 
is also true that the introduction of charged moieties 
enhances the ionization efﬁ  ciency of neutral ste-
roids in ESI and atmospheric pressure chemical 
ionization processes. In P-ESI mode, the picolinoyl 
ester of C4 exhibited an [M+H]
+ ion at m/z 506 as 
the base peak. In the MS/MS spectrum, the 
[M–C6H5O2N]
+ ion was observed at m/z 383 as the 
most prominent peak. The SRM was conducted 
using m/z 506 → m/z 383 for the C4-7α-picolinate 
and m/z 513 → m/z 390 for the [
2H7] variant. The 
detection limit of the C4-7α-picolinate was 30 fg 
(S/N = 3), which was more than 1,000 times more 
sensitive than that of C4 with a conventional HPLC-
UV method. The recovery of spiked C4 was 93.4%, 
and the relative standard deviations between sample 
preparations and between measurements by this 
method were 5.7% and 3.9%, respectively. Thus, 
this LC-MS/MS method is not only the most sensi-
tive method at present for the detection of C4 but 
it is also highly reliable and reproducible.
Applications to Clinical Studies
The quantiﬁ  cation of MVA, 7A or C4 in human 
blood has made it possible to monitor in vivo cho-
lesterol and bile acid synthesis without the need 
for an invasive liver biopsy. Therefore, these meth-
ods are very useful for basic or clinical time-course 
studies of cholesterol metabolism (Table 4).
Diurnal cycle
In 1982, Parker et al. observed the diurnal cycle of 
the MVA concentrations in human plasma (Parker 
et al. 1982). At the peak of the cycle (between mid-
night and 3 a.m.), the MVA concentrations were 3–5 
times greater than those at the nadir (between 9 a.m. 
and noon). Pappu et al. also reported that the plasma 
concentrations of MVA exhibited a diurnal cycle in 
normal subjects and patients with abetalipoprotein-
emia, and the highest levels were observed between 
midnight and 4 a.m. (Pappu and Illingworth, 1994).54
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On the other hand, the diurnal cycle of bile acid 
biosynthesis in the human liver was reported 
(deletion) by Duane et al. (Duane et al. 1983). They 
used a radioisotope technique and demonstrated 
for the ﬁ  rst time that humans with an intact entero-
hepatic circulation exhibited a diurnal cycle of bile 
acid synthesis with an amplitude of ± 35%–55% 
around mean synthesis, and an acrophase at about 
9 a.m. The same group also reported in 1988 that 
neither chenodeoxycholic acid nor ursodeoxycho-
lic acid administration signiﬁ  cantly altered the 
circadian rhythm of bile acid synthesis in humans 
(Pooler and Duane, 1988).
We investigated the diurnal cycle of bile acid 
biosynthesis by using plasma C4 and 7A concen-
trations (Yoshida et al. 1994). Plasma was 
obtained every 2 hours from three normal volun-
teers and the C4 and 7A concentrations were 
determined using our GC-HR-MS method 
(Fig. 3). These levels were ﬁ  tted to a cosine curve 
as reported in the previous studies using the iso-
tope kinetic method (Duane et al. 1983; Pooler 
and Duane, 1988). The amplitudes of C4 and free 
7A averaged 45% and 32%, respectively, and the 
acrophases of C4 and free 7A averaged 5:35 a.m. 
and 5:39 a.m., respectively, which was compat-
ible with the previous results obtained using the 
radioisotope technique (Fig. 4). In contrast, total 
7A and esteriﬁ  ed 7A did not exhibit any signiﬁ  -
cant diurnal cycle.
In 2005, Gälman et al. also reported the diurnal 
cycle of C4 and lathosterol, another biomarker of 
cholesterol biosynthesis (Gälman et al. 2005). 
They concluded that bile acid synthesis in humans 
exhibits a diurnal cycle with 2 peaks during the 
daytime, which is opposite from the circadian 
Figure 2. Representative chromatogram of C4-7α-picolinate by positive ESI-SRM at m/z 506 → m/z 383. Authentic standard of C4-7α-
picolinate (100 fg) was injected into HPLC. LC-MS/MS conditions have been described previously (Honda et al. 2007b).
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rhythm of cholesterol biosynthesis. These results 
were different from previous studies. Further 
investigations will be required to elucidate the 
reason for the discrepancy.
HMGCR inhibitors
The measurement of plasma MVA concentration 
is very useful to evaluate the in vivo effects of 
HMGCR inhibitors. Pfohl et al. reported that the 
HMGCR inhibitor, simvastatin, rapidly down-
regulated cholesterol biosynthesis, which was then 
up-regulated when the drug was withdrawn (Pfohl 
et al. 1998). Nozaki et al. investigated the differ-
ence in the effect of another HMGCR inhibitor, 
pravastatin, on cholesterol biosynthesis between 
the morning and the evening. They administered 
pravastatin to the same patients in the morning or 
evening, and found that morning and evening 
administrations of pravastatin elicited equivalent 
reductions in the plasma and urinary MVA concen-
trations (Nozaki et al. 1996). Pappu and Illingworth 
demonstrated that patients with familial hypercho-
lesterolemia exhibited a diurnal pattern in plasma 
MVA levels similar to that reported previously in 
controls (Pappu and Illingworth, 2002). In addition, 
they reported that the administration of lovastatin 
in the evening reduced the nocturnal increases in 
MVA levels, and the administration of simvastatin 
completely abolished the nighttime rise. Naoumova 
et al. treated familial hypercholesterolemia patients 
with 3 different HMGCR inhibitors, pravastatin, 
simvastatin, and atorvastatin, and showed that the 
patients who responded well to statins exhibited 
higher basal plasma levels of MVA (Naoumova 
et al. 1996).
We investigated the short-term effects of 
pravastatin on cholesterol and bile acid biosynthe-
sis by measuring MVA and C4 as biomarkers 
(Yoshida et al. 1997). Six male volunteers were 
administered 40 mg of pravastatin, and the plasma 
MVA and C4 levels were measured every 2 hours. 
The plasma MVA levels 2 hours after the admin-
istration of pravastatin were decreased compared 
with those in controls. While the decrease in MVA 
concentrations continued for 8 hours, the plasma 
C4 concentrations did not change during the initial 
6 hours and then decreased 8 hours after the admin-
istration. Three-way analysis of this study indicated 
that the MVA level was inﬂ  uenced signiﬁ  cantly by 
Table 4. Applications of MVA and C4 as biomarkers for cholesterol and bile acid biosynthesis.
MVA C4 References
HMGCR inhibitors decrease – (Nozaki, 1996; Naoumova, 1996; 
Yoshida, 1997; Naoumova, 1997; 
Pfohl, 1998; O’Neill, 2001; 
Pappu, 2002)
– no effect (Yoshida, 1997; Naoumova, 1999;
O’Neill, 2001)
HMGCR inhibitors 
with partial ileal 
resection
decrease decrease (Naoumova, 1999)
Insulin decrease – (Lala, 1994; Scoppola, 1995; 
Naoumova, 1996)
Growth hormone no effect – (Boyle, 1992)
– no effect (Leonsson, 1999; Lind, 2004)
Thyroid hormone – no effect (Sauter, 1997)
CDCA – decrease (Einarsson, 2001)
DCA – decrease (Einarsson, 2001)
UDCA – increase (Sauter, 2004)
Rifampin – increase (Lutjohann, 2004)
Gallstone – increase (Muhrbeck, 1997; Gälman, 2004)
Liver cirrhosis no change decrease (Yoshida, 1999)
Diarrhea – increase (Eusufzai, 1993; Sauter, 1999)56
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both pravastatin treatment and the time-course. In 
contrast, C4 level was affected signiﬁ  cantly by 
both inter-individual differences and time-course, 
but not by pravastatin treatment. These results 
indicated that cholesterol biosynthesis was inhib-
ited by pravastatin treatment, but bile acid biosyn-
thesis was not influenced in normal subjects 
(Yoshida et al. 1997). Naoumova et al. treated 
familial hypercholesterolemia patients with ator-
vastatin and partial ileal bypass (Naoumova et al. 
1999). Atorvastatin decreased the rate of bile acid 
synthesis only when bile acid synthesis was up-
regulated by partial ileal bypass or bile acid seques-
trants, presumably by limiting the supply of newly 
synthesized free cholesterol.
Hormones
There are several reports that show the effects of 
hormones e.g. insulin, growth hormone and thyroid 
hormone, on in vivo cholesterol metabolism. 
Euglycemic hyperinsulinemia acutely decreased 
the circulating levels of MVA (Lala et al. 1994), 
which indicated that insulin could decrease 
cholesterol biosynthesis. Naoumova et al. also 
investigated the effects of hyperinsulinemia on the 
plasma MVA concentrations and reported that acute 
hyperinsulinemia decreased cholesterol biosynthe-
sis less in the subjects with non-insulin-dependent 
diabetes mellitus compared with non-diabetic 
subjects, which suggests that the patients with 
non-insulin-dependent diabetes mellitus exhibit 
insulin resistance (Naoumova et al. 1996).
Because plasma growth hormone levels and 
cholesterol biosynthesis are both increased during 
sleep, Boyle et al. speculated that growth hormone 
might stimulate de novo cholesterol biosynthesis 
(Boyle et al. 1992). However, the peak nocturnal 
and fasting MVA concentrations did not correlate 
with the growth hormone levels, and they con-
cluded that nocturnal growth hormone secretion 
was not related to the stimulation of cholesterol 
production during sleep.
Patients with hypothyroidism exhibit hypercho-
lesterolemia, while those with hyperthyroidism 
exhibit hypocholesterolemia. Sauter et al. mea-
sured serum C4 concentrations before and after 
treatment for hypo- and hyperthyroidism and 
Figure 3. The circadian rhythm of the plasma levels of C4 and 7A in three normal volunteers. The volunteers consumed a normal hospital 
diet three times a day (shown by arrows), and slept from 21:00 on the ﬁ  rst day to 6:00 on the second day (shown by the shaded box). The 
values are expressed as fractional variations around the mean levels (mean ± SD). Dashed lines represent the curves of best ﬁ  t. (A) C4; 
(B) free 7A; (C) esteriﬁ  ed 7A; (D) total 7A. Reprinted with minor modiﬁ  cation from our previous paper (Yoshida et al. 1994), Copyright (1994), 
with permission from Elsevier.57
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showed that in humans, thyroid hormones 
inﬂ  uenced the serum cholesterol concentrations by 
mechanisms other than through modiﬁ  cation of the 
CYP7A1 activity (Sauter et al. 1997).
Bile acids
Bile acids, particularly chenodeoxycholic acid 
(CDCA) and deoxycholic acid (DCA), are physi-
ological ligands for the farnesoid X receptor (FXR, 
NR1H4). They inhibit bile acid biosynthesis 
through activation of this nuclear receptor. In fact, 
Einarsson et al. reported that the treatment of 
healthy subjects with CDCA or DCA reduced the 
serum concentrations of C4 (Einarsson et al. 2001). 
They also found that CDCA reduced cholesterol 
biosynthesis while DCA did not when they evalu-
ated in vivo cholesterol biosynthesis by measuring 
the serum 7-dehydrocholesterol concentrations. In 
contrast, UDCA treatment for 40 days did not affect 
cholesterol synthesis, as evaluated by urinary excre-
tion of MVA, but the same treatment signiﬁ  cantly 
increased bile acid biosynthesis determined by 
serum C4 concentrations (Sauter et al. 2004).
Hepatobiliary diseases
Cholesterol gallstone disease is caused by abnormal 
cholesterol and bile acid metabolism. The formation 
of cholesterol supersaturated bile is one of the 
important factors in the pathogenesis of this dis-
ease. Shoda et al. proposed an estimated biliary 
cholesterol saturation index (CSI)E = 1[MVL] + 
0.7[C4] that was calculated by multivariate linear 
regression analysis using the plasma MVA and C4 
concentrations of patients with hyperlipoprotein-
emia and demonstrated that this convenient calcu-
lation of (CSI)E corresponded well to actual biliary 
CSI (Shoda et al. 1997). However, the hypersecre-
tion of biliary cholesterol in patients with gall-
stones does not seem to be due to increased hepatic 
synthesis of cholesterol or decreased catabolism 
of cholesterol to bile acids. This could be because 
the plasma levels of lathosterol were not signiﬁ  cantly 
different between gallstone subjects and controls 
and the C4 levels were about 40% higher in the 
gallstone subjects compared with the controls 
(Muhrbeck et al. 1997). The increased bile acid 
biosynthesis determined by the plasma C4 levels, 
corrected for plasma cholesterol, was also reported 
in gallstone subjects and gallstone high-risk Mapu-
che Indians (Gälman et al. 2004).
Conversely, some hepatobiliary diseases affect 
cholesterol and bile acid metabolism. In patients 
with liver cirrhosis (LC), the blood cholesterol 
levels are relatively preserved, despite other 
Figure 4. The curves of best ﬁ  t for C4 and 7A. (A) C4, y = 0.46 cos ((2π/24)t - 1.46) (p  0.005); (B) Free 7A, y = 0.32 cos ((2π/24)t - 1.48) 
(p  0.005); (C) Esteriﬁ  ed 7A, 0.12 cos ((2π/24)t + 0.97) (NS); (D) Total 7A, 0.07 cos ((2π/24)t - 0.65) (NS). Statistical signiﬁ  cance was 
evaluated by a Zero-amplitude test by Nelson et al. (Nelson et al. 1979). Reprinted with minor modiﬁ  cation from our previous paper (Yoshida 
et al. 1994), Copyright (1994), with permission from Elsevier.58
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markers, including the serum albumin levels, show 
liver dysfunction. We studied the association 
between hepatic cholesterogenesis and bile acid 
synthesis in hepatocellular impairment using the 
plasma levels of MVA and C4 (Yoshida et al. 
1999). There were no signiﬁ  cant differences in the 
plasma MVA levels between chronic hepatitis 
(CH), LC and control groups. In contrast, plasma 
C4 levels were signiﬁ  cantly lower in LC compared 
with the CH and control groups. Although the MVA 
levels did not correlate with the Child-Pugh’s 
score, which reﬂ  ects the severity of liver damage 
(Albers et al. 1989), there was a signiﬁ  cant cor-
relation between the C4 level and Child-Pugh’s 
score. In addition, plasma C4 levels in the control 
subjects correlated positively with the MVA levels, 
but there was no signiﬁ  cant correlation between 
these biomarkers in CH and LC patients. Therefore, 
it was concluded that in the patients with chronic 
liver disease, there was a tendency for hepatic 
cholesterogenesis to be sustained in the face of 
hepatocellular dysfunction, while bile acid synthe-
sis declined in parallel with the severity of impair-
ment.
Perspectives
Biological specimens contain many types of 
organic acids and sterols. While fatty acids and 
cholesterol are relatively abundant compounds, 
MVA and oxysterols (7A and C4) are minor com-
ponents. To quantify the concentrations of such 
minor components, stable isotope dilution mass 
spectrometry (GC-MS or LC-MS/MS) is an ideal 
method because of its high sensitivity, speciﬁ  city 
and accuracy.
Recently, LC-MS/MS has come to be used more 
readily than GC-MS. Because MS/MS is more 
speciﬁ  c than MS, sample preparation process for 
the elimination of interfering materials can be 
simplified. In addition, LC-MS/MS does not 
require a derivatization step, which is also advan-
tageous for high-throughput analyses. However, 
simple and rapid procedures do not always produce 
good results for the microanalysis of biological 
samples. A careful sample puriﬁ  cation can increase 
the sensitivity of an analyte by reducing matrix 
effect (Jemal et al. 2003). Derivatization is useful 
not only to increase the sensitivity by enhancing 
the ionization efﬁ  ciency but also to give a promi-
nent ion in the high mass region, which makes it 
possible to avoid interfering peaks and to increase 
the speciﬁ  city. A thorough chromatographic sepa-
ration is also important to distinguish between 
similar biological compounds, e.g. hydroxycho-
lesterols that have the same molecular weight and 
a virtually identical MS/MS spectrum. Thus, the 
importance of basic analytical techniques, i.e. 
sample puriﬁ  cation, derivatization and chromato-
graphic separation will not be denied even if the 
performance of mass spectrometer is improved 
further.
In conclusion, the methods for the quantiﬁ  cation 
of key intermediates in cholesterol and bile acid 
biosynthetic pathways using stable isotope dilution 
mass spectrometry exhibit superior accuracy and 
sensitivity. By using this technique, the MVA and 
oxysterols in blood were established as biomarkers 
for cholesterol and bile acid biosynthesis. The use 
of these biomarkers has made it possible to moni-
tor in vivo cholesterol and bile acid synthesis 
without the need for invasive liver biopsy, which 
is very useful for basic or clinical studies of cho-
lesterol metabolism in humans.
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